Showing results (371-380 of 528) with videos related to
Sort By:
Pageof 53
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell, Barney S Graham, Michael C Keefer, et al.Nature Medicine|August 25, 2015
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protectionHadi M Yassine, Jeffrey C Boyington, Patrick M McTamney, et al.Plos One|May 9, 2020
Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirusJang-Hoon Choi, Hye-Min Woo, Tae-Young Lee, et al.Iscience|September 28, 2023
Refined semi-lethal aerosol H5N1 influenza model in cynomolgus macaques for evaluation of medical countermeasuresMasaru Kanekiyo, Rebecca A Gillespie, Morgan Midgett, et al.Cell Reports|October 28, 2021
Stabilized coronavirus spike stem elicits a broadly protective antibodyChing-Lin Hsieh, Anne P Werner, Sarah R Leist, et al.NPJ Vaccines|August 8, 2023
Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic deliveryCuiping Liu, Lingshu Wang, Jonah S Merriam, et al.Biorxiv : the Preprint Server for Biology|July 18, 2020
A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike AloneBaoshan Zhang, Cara W Chao, Yaroslav Tsybovsky, et al.Nature Communications|August 1, 2025
Structural convergence and water-mediated substrate mimicry enable broad neuraminidase inhibition by human antibodiesJulia Lederhofer, Andrew J Borst, Lam Nguyen, et al.Plos Medicine|November 15, 2017
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H Mayer, Kelly E Seaton, Yunda Huang, et al.Biorxiv : the Preprint Server for Biology|December 23, 2024
Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccinesSandhya Bangaru, Abigail M Jackson, Jeffrey Copps, et al.Pageof 53